Key Novartis drug faces delay
13024
U.S. regulators have asked for more data on Novartis AG's  diabetes drug Galvus, possibly delaying approval of the potential blockbuster by a year, which dented its shares while boosting its main rival's.
573459
A key study of its lead drug proceeds faster than expected.
148195
The supply of low-cost generic versions of cancer and AIDS treatments for the developing world could be blocked if Novartis wins a legal challenge to Indiaâs patent law.
614544
A new group of patients that qualifies for Medicare reimbursement for implantable heart defibrillators may have to wait a few days longer until payment is available, the federal government said on Thursday.
149716
German drug maker Altana said that it had postponed its application for approval of its new asthma treatment Roflumilast in the United States in order to undertake additional clinical trials on the drug.
286537
A battle between insurers and drug companies could determine how many medicines will be available to beneficiaries.
672526
Merck & Co. MRK.N said on Friday it   would delay seeking approval for a combination pill designed to   lower "bad" cholesterol, increase "good" cholesterol and avoid   a common side effect of one of the ingredients.
458999
Merck & Co.  said on Friday it  would delay seeking approval for a combination pill designed to  lower "bad" cholesterol, increase "good" cholesterol and avoid  a common side effect of one of the ingredients.
615675
A new group of patients that qualifies  for Medicare reimbursement for implantable heart defibrillators  may have to wait a few days longer until payment is available,  the federal government said on Thursday.
459813
Time is running out for Boston Scientific to resolve what could be a multibillion-dollar liability resulting from its foray into the stent business.
593038
Clinical trial results show significant   benefits for patients with relapsing multiple sclerosis treated   with Novartis's experimental FTY720 medicine, the company said   late on Wednesday.
766518
A study shows promising results for Novartis's COX-2 inhibitor.
539761
GlaxoSmithKline PLC and Novartis AG, two of the world's biggest vaccine makers, may have bet on the wrong technology in the race to develop a better flu shot.
415157
Daniel L. Vasella, chief executive of Novartis, discusses the challenges facing the health care system.
104063
The FDA has another delay for this HPV vaccine.
741225
Chiron Corp. is delaying shipment of  its flu vaccine, Fluvirin,  because lots containing 4 million  vaccines, do not meet product sterility standards, the  pharmaceutical company said on Thursday .
250837
U.S. regulators have not approved Novartis AG's Prexige painkiller, the Swiss drugmaker said on Thursday, a move that had been expected after Australia withdrew the drug on concerns over liver side-effects.